Staar Surgical says no acquisition proposals received except from Alcon

STAAR Surgical (STAA) Company issued the following statement: “Broadwood Partners’ statements and assertions regarding interest in STAAR are misleading and distort the truth. Broadwood is misrepresenting introductory emails as offers to acquire STAAR. As previously disclosed, the communications from Party A and B were not offers and contained no information relating to valuation, timing, diligence requirements, financing capability, transaction structure, or other terms. Similarly, as disclosed in STAAR’s Form 8-K filing with the SEC on October 14, 2025, a representative of a privately-owned company also emailed STAAR on April 7, 2025. Since the Form 8-K filing, Party C has confirmed to STAAR that “the outreach was an introductory email and was not intended as a proposal.” The email was not followed up on by Party C… We urge all STAAR stockholders not to be misled by Broadwood. STAAR is confident that the Alcon transaction maximizes value for STAAR stockholders, is the only merger transaction available to the Company and if it is not approved, the value of your shares is at risk of declining substantially. Time is short. The Special Meeting is fast approaching. We encourage all STAAR stockholders to vote ‘FOR’ the Alcon merger on the WHITE proxy card TODAY. STAAR will hold a virtual Special Meeting of Stockholders on October 23 at 8:30 a.m. (Pacific Time) to vote on the Alcon merger. Stockholders of record as of the close of business on September 12, 2025, are entitled to vote at the meeting. The STAAR Board of Directors has unanimously approved the merger and recommended that all STAAR stockholders vote “FOR” the merger proposal on the WHITE proxy card TODAY.”